Lobbying disclosures · Lobbying report
MDGL: third_quarter 2026 lobbying report
FDA and regulatory issues related to the biopharmaceutical industry. FDA and regulatory issues related to the biopharmaceutical industry. FDA and regulatory issues related to the biopharmaceutical industry, including CMMI Drug Pricing Models.
Follow MDGL- Became public
- Oct 20, 2026, 3:55 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 6:37 PM EST
Why this is connected
Exact legal-name match: MADRIGAL PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/1157601/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/69aee5e9-b2a8-48bb-96f8-1fcfe619d1a1/","filing_uuid":"69aee5e9-b2a8-48bb-96f8-1fcfe619d1a1","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/69aee5e9-b2a8-48bb-96f8-1fcfe619d1a1/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Allegra M. Han","dt_posted":"2026-10-20T15:55:05-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 13th Street NW, 2nd Floor","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":313715,"url":"https://lda.gov/api/v1/registrants/313715/","house_registrant_id":39384,"name":"CAPITOL COUNSEL LLC","description":"Government affairs.","address_1":"700 13th Street NW, 2nd Floor","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"TRACEY A. GRAY","contact_telephone":"+1 202-861-3200","dt_updated":"2026-07-31T14:55:49.985763-04:00"},"client":{"id":71323,"url":"https://lda.gov/api/v1/clients/71323/","client_id":71323,"name":"MADRIGAL PHARMACEUTICALS, INC.","general_description":"Biopharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"FDA and regulatory issues related to the biopharmaceutical industry.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70388,"prefix":null,"prefix_display":null,"first_name":"LYNDON","nickname":null,"middle_name":null,"last_name":"BOOZER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143156,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153079,"prefix":"mr","prefix_display":"MR.","first_name":"CHARLES","nickname":null,"middle_name":"PATRICK","last_name":"MICHAELS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148273,"prefix":null,"prefix_display":null,"first_name":"GEORGE","nickname":null,"middle_name":null,"last_name":"SIFAKIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":45351,"prefix":null,"prefix_display":null,"first_name":"SHANNON","nickname":null,"middle_name":null,"last_name":"FINLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":110089,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"CARROLL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65069,"prefix":null,"prefix_display":null,"first_name":"ANN","nickname":null,"middle_name":null,"last_name":"JABLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"FDA and regulatory issues related to the biopharmaceutical industry.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70388,"prefix":null,"prefix_display":null,"first_name":"LYNDON","nickname":null,"middle_name":null,"last_name":"BOOZER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143156,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153079,"prefix":"mr","prefix_display":"MR.","first_name":"CHARLES","nickname":null,"middle_name":"PATRICK","last_name":"MICHAELS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148273,"prefix":null,"prefix_display":null,"first_name":"GEORGE","nickname":null,"middle_name":null,"last_name":"SIFAKIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":45351,"prefix":null,"prefix_display":null,"first_name":"SHANNON","nickname":null,"middle_name":null,"last_name":"FINLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":110089,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"CARROLL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65069,"prefix":null,"prefix_display":null,"first_name":"ANN","nickname":null,"middle_name":null,"last_name":"JABLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"FDA and regulatory issues related to the biopharmaceutical industry, including CMMI Drug Pricing Models.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70388,"prefix":null,"prefix_display":null,"first_name":"LYNDON","nickname":null,"middle_name":null,"last_name":"BOOZER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143156,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153079,"prefix":"mr","prefix_display":"MR.","first_name":"CHARLES","nickname":null,"middle_name":"PATRICK","last_name":"MICHAELS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148273,"prefix":null,"prefix_display":null,"first_name":"GEORGE","nickname":null,"middle_name":null,"last_name":"SIFAKIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":45351,"prefix":null,"prefix_display":null,"first_name":"SHANNON","nickname":null,"middle_name":null,"last_name":"FINLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":110089,"prefix":null,"prefix_display":null,"first_name":"JEFFREY","nickname":null,"middle_name":null,"last_name":"CARROLL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65069,"prefix":null,"prefix_display":null,"first_name":"ANN","nickname":null,"middle_name":null,"last_name":"JABLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in MDGL
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- May 19, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold Madrigal Pharmaceuticals MDGL
$1K–$15K · Traded Apr 10, 2023 · disclosed May 19, 2023
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.